Video
Dr. Maughan Discusses Abiraterone Plus Olaparib in mCRPC
Author(s):
Benjamin Maughan, MD, PharmD, instructor, Division of Medical Oncology, Huntsman Cancer Institute, discusses the combination of abiraterone acetate (Zytiga) and olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer.
Benjamin Maughan, MD, PharmD, instructor, Division of Medical Oncology, Huntsman Cancer Institute, discusses the combination of abiraterone acetate (Zytiga) and olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer (mCRPC).
The combination of the antiandrogen agent abiraterone and the PARP inhibitor olaparib demonstrated a 35% reduction in the risk of disease progression or death compared with abiraterone alone in pretreated patients with mCRPC. Findings presented at the 2018 ASCO Annual Meeting demonstrated a median progression-free survival of 13.8 months with the combination compared with 8.2 months with single-agent abiraterone (HR, 0.65; 95% CI, 0.44-0.97; P = .034).
Maughan says that although these are positive results, another study of abiraterone plus a PARP inhibitor—veliparib—showed a benefit only in biomarker-positive patients. This makes interpreting the results with abiraterone plus olaparib a challenge, he adds, as some of the data are contradictory. More details on the different patient populations needs to be released after further investigation is completed.
